Their guidelines are widely heeded by health care professionals and even influence the insurance coverage of certain preventive services.
In 2017, the USPSTF recommended that children should be routinely screened for obesity.
Children with obesity should then be referred to comprehensive, intensive behavioral interventions.
Semaglutide is the active ingredient in type 2 diabetes medication Ozempic, seen above, and obesity medication Wegovy. Wegovy was approved for children 12 and older with obesity in December 2022.Photo: Jaap Arriens (Getty Images)
But they are continuing to champion the use of intensive behavioral interventions for child obesity.
So that means interventions that are 26 hours or more in terms of the time.
The USPSTF typically revisits its guidelines every five years.
So its certainly possible that their verdict will change by then.
And the group is openly pushing for scientists to collect the information needed to know for sure.
So we really want researchers to prioritize this question.
News from the future, delivered to your present.
Does Ozempic Really Cause Thyroid Cancer?
Ozempic Not Working for You?
A Staggering Number of U.S.
